Clinical trial coordination under the evaluation system of investigational medical care in Japan: Operational challenges in multi-center cancer clinical trials

Eriko Aotani, Tomomi Hata, Atsuko Kawakami, Sae Tsuboi, Nami Numagami, Mayumi Ushitani, Kaoru Miyata, Miwa Nonaka, Masahiro Takeuchi, Toru Takebayashi, Keiichi Fujiwara

研究成果: Article

抄録

The Evaluation System of Investigational Medical Care (ESIMeC) is a new clinical trial system that Ministry of Health, Labour and Welfare authorizes the coverage of medical expenses by Japanese health insurance system for the patients participating in the approved clinical trials with high quality control mechanism. This system became effective in 2008. The Kitasato University Clinical Trials Coordinating Center has supported two randomized, phase III trials being conducted under ESIMeC since 2009. One trial is to evaluate the efficacy and safety of intraperitoneal (IP) chemotherapy of Carboplatin for ovarian cancer patients ; another trial is to evaluate the efficacy and safety of new anticancer agent Bevacizumab for recurrent ovarian cancer patients. Carboplatin is approved for ovarian cancer by intravenous administration, but not for IP administration. Bevacizumab is not approved for ovarian cancer. However, the indication-directed trial has been completed for the first line chemotherapy for ovarian cancer, but not for the recurrent setting. In this article, we discuss the issues that need to be improved in the future, as well as the importance of the clinical trial coordinating center, so that ESIMeC will work better to accelerate investigator-initiated clinical trials evaluating new agents/medical techniques with no indication approval in Japan. Critical issues in cancer clinical trial coordination under ESIMeC include being familiar with the system itself, development of the clinical trial team, support of the application process for ESIMeC, establishment of serious adverse event reporting procedures, management of the study agents, and cost-effective study monitoring.

元の言語English
ジャーナルJapanese Pharmacology and Therapeutics
40
発行部数SUPPL. 1
出版物ステータスPublished - 2012 3 25
外部発表Yes

Fingerprint

Japan
Clinical Trials
Ovarian Neoplasms
Neoplasms
Carboplatin
Safety
Drug Therapy
Health Insurance
Quality Control
Intravenous Administration
Antineoplastic Agents
Research Personnel
Costs and Cost Analysis
Health
Bevacizumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

これを引用

Clinical trial coordination under the evaluation system of investigational medical care in Japan : Operational challenges in multi-center cancer clinical trials. / Aotani, Eriko; Hata, Tomomi; Kawakami, Atsuko; Tsuboi, Sae; Numagami, Nami; Ushitani, Mayumi; Miyata, Kaoru; Nonaka, Miwa; Takeuchi, Masahiro; Takebayashi, Toru; Fujiwara, Keiichi.

:: Japanese Pharmacology and Therapeutics, 巻 40, 番号 SUPPL. 1, 25.03.2012.

研究成果: Article

Aotani, E, Hata, T, Kawakami, A, Tsuboi, S, Numagami, N, Ushitani, M, Miyata, K, Nonaka, M, Takeuchi, M, Takebayashi, T & Fujiwara, K 2012, 'Clinical trial coordination under the evaluation system of investigational medical care in Japan: Operational challenges in multi-center cancer clinical trials', Japanese Pharmacology and Therapeutics, 巻. 40, 番号 SUPPL. 1.
Aotani, Eriko ; Hata, Tomomi ; Kawakami, Atsuko ; Tsuboi, Sae ; Numagami, Nami ; Ushitani, Mayumi ; Miyata, Kaoru ; Nonaka, Miwa ; Takeuchi, Masahiro ; Takebayashi, Toru ; Fujiwara, Keiichi. / Clinical trial coordination under the evaluation system of investigational medical care in Japan : Operational challenges in multi-center cancer clinical trials. :: Japanese Pharmacology and Therapeutics. 2012 ; 巻 40, 番号 SUPPL. 1.
@article{5208d67e957c4f2690e24c519c1d7710,
title = "Clinical trial coordination under the evaluation system of investigational medical care in Japan: Operational challenges in multi-center cancer clinical trials",
abstract = "The Evaluation System of Investigational Medical Care (ESIMeC) is a new clinical trial system that Ministry of Health, Labour and Welfare authorizes the coverage of medical expenses by Japanese health insurance system for the patients participating in the approved clinical trials with high quality control mechanism. This system became effective in 2008. The Kitasato University Clinical Trials Coordinating Center has supported two randomized, phase III trials being conducted under ESIMeC since 2009. One trial is to evaluate the efficacy and safety of intraperitoneal (IP) chemotherapy of Carboplatin for ovarian cancer patients ; another trial is to evaluate the efficacy and safety of new anticancer agent Bevacizumab for recurrent ovarian cancer patients. Carboplatin is approved for ovarian cancer by intravenous administration, but not for IP administration. Bevacizumab is not approved for ovarian cancer. However, the indication-directed trial has been completed for the first line chemotherapy for ovarian cancer, but not for the recurrent setting. In this article, we discuss the issues that need to be improved in the future, as well as the importance of the clinical trial coordinating center, so that ESIMeC will work better to accelerate investigator-initiated clinical trials evaluating new agents/medical techniques with no indication approval in Japan. Critical issues in cancer clinical trial coordination under ESIMeC include being familiar with the system itself, development of the clinical trial team, support of the application process for ESIMeC, establishment of serious adverse event reporting procedures, management of the study agents, and cost-effective study monitoring.",
keywords = "Clinical Research Management, Clinical Trail, Evaluation System of Investigational Medical Care (ESIMeC)",
author = "Eriko Aotani and Tomomi Hata and Atsuko Kawakami and Sae Tsuboi and Nami Numagami and Mayumi Ushitani and Kaoru Miyata and Miwa Nonaka and Masahiro Takeuchi and Toru Takebayashi and Keiichi Fujiwara",
year = "2012",
month = "3",
day = "25",
language = "English",
volume = "40",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Clinical trial coordination under the evaluation system of investigational medical care in Japan

T2 - Operational challenges in multi-center cancer clinical trials

AU - Aotani, Eriko

AU - Hata, Tomomi

AU - Kawakami, Atsuko

AU - Tsuboi, Sae

AU - Numagami, Nami

AU - Ushitani, Mayumi

AU - Miyata, Kaoru

AU - Nonaka, Miwa

AU - Takeuchi, Masahiro

AU - Takebayashi, Toru

AU - Fujiwara, Keiichi

PY - 2012/3/25

Y1 - 2012/3/25

N2 - The Evaluation System of Investigational Medical Care (ESIMeC) is a new clinical trial system that Ministry of Health, Labour and Welfare authorizes the coverage of medical expenses by Japanese health insurance system for the patients participating in the approved clinical trials with high quality control mechanism. This system became effective in 2008. The Kitasato University Clinical Trials Coordinating Center has supported two randomized, phase III trials being conducted under ESIMeC since 2009. One trial is to evaluate the efficacy and safety of intraperitoneal (IP) chemotherapy of Carboplatin for ovarian cancer patients ; another trial is to evaluate the efficacy and safety of new anticancer agent Bevacizumab for recurrent ovarian cancer patients. Carboplatin is approved for ovarian cancer by intravenous administration, but not for IP administration. Bevacizumab is not approved for ovarian cancer. However, the indication-directed trial has been completed for the first line chemotherapy for ovarian cancer, but not for the recurrent setting. In this article, we discuss the issues that need to be improved in the future, as well as the importance of the clinical trial coordinating center, so that ESIMeC will work better to accelerate investigator-initiated clinical trials evaluating new agents/medical techniques with no indication approval in Japan. Critical issues in cancer clinical trial coordination under ESIMeC include being familiar with the system itself, development of the clinical trial team, support of the application process for ESIMeC, establishment of serious adverse event reporting procedures, management of the study agents, and cost-effective study monitoring.

AB - The Evaluation System of Investigational Medical Care (ESIMeC) is a new clinical trial system that Ministry of Health, Labour and Welfare authorizes the coverage of medical expenses by Japanese health insurance system for the patients participating in the approved clinical trials with high quality control mechanism. This system became effective in 2008. The Kitasato University Clinical Trials Coordinating Center has supported two randomized, phase III trials being conducted under ESIMeC since 2009. One trial is to evaluate the efficacy and safety of intraperitoneal (IP) chemotherapy of Carboplatin for ovarian cancer patients ; another trial is to evaluate the efficacy and safety of new anticancer agent Bevacizumab for recurrent ovarian cancer patients. Carboplatin is approved for ovarian cancer by intravenous administration, but not for IP administration. Bevacizumab is not approved for ovarian cancer. However, the indication-directed trial has been completed for the first line chemotherapy for ovarian cancer, but not for the recurrent setting. In this article, we discuss the issues that need to be improved in the future, as well as the importance of the clinical trial coordinating center, so that ESIMeC will work better to accelerate investigator-initiated clinical trials evaluating new agents/medical techniques with no indication approval in Japan. Critical issues in cancer clinical trial coordination under ESIMeC include being familiar with the system itself, development of the clinical trial team, support of the application process for ESIMeC, establishment of serious adverse event reporting procedures, management of the study agents, and cost-effective study monitoring.

KW - Clinical Research Management

KW - Clinical Trail

KW - Evaluation System of Investigational Medical Care (ESIMeC)

UR - http://www.scopus.com/inward/record.url?scp=84859652182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859652182&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84859652182

VL - 40

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - SUPPL. 1

ER -